RF21 | PSAT93 Improvement of Final Height in Congenital Adrenal Hyperplasia Patients Treated With Recombinant Growth Hormone

 : Final height (FH) in congenital adrenal hyperplasia (CAH) patients is frequently under -1.5 SDS in relation to the normal population, even in those with good compliance, chronic androgen exposure or supraphysiological glucocorticoid doses could corroborate to this finding. Recombinant human growt...

Descripción completa

Detalles Bibliográficos
Autores principales: Costa, Fernanda C, de Sousa, Donaldt L, Madureira, Guiomar, Mathias, Patrícia M B R, Mendonca, Berenice B, Miranda, Mirela C, Silva, Mylena C M, Bachega, Tânia A S S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Adrenal
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624678/
http://dx.doi.org/10.1210/jendso/bvac150.281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9624678/
http://dx.doi.org/10.1210/jendso/bvac150.281

Ejemplares similares